Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02093533

Eculizumab in Primary MPGN — EAGLE  

Membranoproliferative Glomerulonephritis Clinical Trial

Official title:
EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA

Clinical Trial Summary

Membranoproliferative glomerulonephritis (MPGN) is the third or fourth leading cause of end stage renal disease among the primary glomerulonephritis. Hyperactivation of the alternative complement pathway and familial forms for all types of MPGN have been reported suggesting that genetic abnormalities may play a predisposing role to the disease. In recent case reports Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex ,is a safe and effective therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Glomerulonephritis
  • Glomerulonephritis, Membranoproliferative
  • Membranoproliferative Glomerulonephritis
Clinical Trial Details
NCT number NCT02093533
Study type Interventional
Source Mario Negri Institute for Pharmacological Research
Contact
Status Completed
Phase Phase 2
Start date March 2014
Completion date December 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT03095118 - Daratumumab in Treatment of PGNMID and C3 GN Phase 2
Recruiting NCT05985122 - New Analytic Tools for aHUS and C3G Diagnosis N/A
Recruiting NCT04183101 - Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Phase 2
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Active, not recruiting NCT05067127 - Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Phase 3
Active, not recruiting NCT05809531 - An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Phase 3
Completed NCT01221181 - Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Phase 1
Not yet recruiting NCT03180723 - Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis Phase 3
Active, not recruiting NCT04572854 - Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Phase 2
Recruiting NCT05996731 - Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases N/A
Available NCT04729062 - C3G/Primary IC-MPGN EAP